For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 19,025,832 | |||
| General and administrative expenses | 12,518,127 | |||
| Total operating expenses | 31,543,959 | |||
| Loss from operations | -31,543,959 | |||
| Interest income | 1,217,241 | |||
| Interest expense | 5,338,607 | |||
| Interest income (expenses), net | -4,121,366 | |||
| Loss before income taxes | -35,665,325 | |||
| Benefit for income taxes | -1,169,820 | |||
| Net loss | -34,495,505 | |||
| Basic EPS | -0.74 | |||
| Diluted EPS | -0.74 | |||
| Basic Average Shares | 46,384,280 | |||
| Diluted Average Shares | 46,384,280 | |||
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)